Redburn Atlantic upgraded Alcon from Sell to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | Sell → Neutral | Redburn Atlantic | |
| 9/10/2024 | Sector Perform → Outperform | RBC Capital Mkts | |
| 7/15/2024 | $65.00 → $85.00 | Underweight → Equal-Weight | Morgan Stanley |
| 5/15/2024 | $103.00 | Perform → Outperform | Oppenheimer |
| 4/10/2024 | $100.00 | Buy | Goldman |
| 3/14/2024 | Sector Perform | RBC Capital Mkts | |
| 2/6/2024 | $87.00 | Overweight | KeyBanc Capital Markets |
| 1/23/2024 | $94.40 | Outperform | Bernstein |
Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17. Earnings Estimates: Analysts expect Johnson & Johnson to report second-quarter revenue of $22.31 billion, according to data from Benzinga Pro. The company reported revenue of $25.53 billion in last year's second quarter, meaning analysts see a revenue decline on a year-over-year basis. Johnson & Johnson has beaten revenue estimates in six of the past 10 quarters and four of the last five quarters.
BTIG analyst Ryan Zimmerman maintains Alcon (NYSE:ALC) with a Buy and raises the price target from $92 to $96.
Morgan Stanley analyst Patrick Wood upgrades Alcon (NYSE:ALC) from Underweight to Equal-Weight and raises the price target from $65 to $85.
Record Q2 2024 sales of $2.5 billion, up 3%, or 6% constant currency1 (cc) Q2 2024 diluted EPS of $0.45, up 32%, or 47% cc; core diluted EPS2 of $0.74, up 7%, or 15% cc H1 2024 cash from operations of $871 million; free cash flow3 of $667 million, up $478 million, or 253% Received U.S. FDA clearance of Unity VCS/CS and PDUFA date for AR-15512 of May 30th, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as
First-quarter 2024 sales of $2.4 billion, up 5%, or 7% constant currency1 (cc) First-quarter 2024 diluted EPS of $0.50, up 43%, or 62% cc; core diluted EPS2 of $0.78 up 11%, or 21% cc First-quarter 2024 cash from operations of $341 million; free cash flow3 of $229 million, up $248 million year-over year Dividend of CHF 0.24 per share approved by shareholders at the Annual General Meeting on May 8, 2024 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2024. For the first quarter of 2024, sales were $2.4 billion, an increase of 5% on a reported basis and 7% on a consta
Shareholders approve dividend of CHF 0.24 per share Shareholders confirm F. Michael Ball as member and Chair of the Board of Directors as well as the other members who all stood for re-election Shareholders approve the 2023 Non-Financial Matters Report in an advisory vote Shareholders approve the Board and Executive Committee compensation in separate binding votes Alcon Inc. (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed binding resolutions at its 2024 Annual General Meeting (AGM). A total of 326,707,870 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of
Redburn Atlantic upgraded Alcon from Sell to Neutral
RBC Capital Mkts upgraded Alcon from Sector Perform to Outperform
Morgan Stanley upgraded Alcon from Underweight to Equal-Weight and set a new price target of $85.00 from $65.00 previously
Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting
Attendees can experience a first look at Voyager DSLT, Alcon's new first-line laser therapy for glaucoma patients Alcon introduces new handheld gas delivery systems, UNIFEYE and UNIPEXY, optimizing convenience and accuracy for retina surgeons In addition, Alcon presents pivotal data for AR-15512 (acoltremon 0.003%)*, a prescription drug candidate undergoing FDA review for the treatment of dry eye Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, will showcase its latest clinical data and product innovations at the upcoming American Academy of Ophthalmology (AAO) 2024 annual meeting. Ophthalmologists, surgical staff, researchers, and industry
Record Q2 2024 sales of $2.5 billion, up 3%, or 6% constant currency1 (cc) Q2 2024 diluted EPS of $0.45, up 32%, or 47% cc; core diluted EPS2 of $0.74, up 7%, or 15% cc H1 2024 cash from operations of $871 million; free cash flow3 of $667 million, up $478 million, or 253% Received U.S. FDA clearance of Unity VCS/CS and PDUFA date for AR-15512 of May 30th, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and six month periods ending June 30, 2024. For the second quarter of 2024, sales were $2.5 billion, an increase of 3% on a reported basis and 6% on a constant currency basis1, as
Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation Alcon to immediately begin collecting real-world user experience in the U.S. prior to broad commercialization in 2025 First innovations to be introduced from Alcon's cutting-edge Unity portfolio of surgical equipment Ad Hoc Announcement Pursuant to Art. 53 LR Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS) have received U.S. Food and Drug Admi
6-K - ALCON INC (0001167379) (Filer)
6-K - ALCON INC (0001167379) (Filer)
SD - ALCON INC (0001167379) (Filer)
SC 13G - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)
SC 13G/A - ALCON INC (0001167379) (Subject)